Monovalent inactivated influenza vaccine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prepandemic Influenza Vaccine
Conditions
Prepandemic Influenza Vaccine
Trial Timeline
Dec 1, 2008 → Nov 1, 2009
NCT ID
NCT00841646About Monovalent inactivated influenza vaccine
Monovalent inactivated influenza vaccine is a phase 2 stage product being developed by Novartis for Prepandemic Influenza Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT00841646. Target conditions include Prepandemic Influenza Vaccine.
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00841646 | Phase 2 | Completed |
| NCT00848029 | Phase 3 | Completed |